In this study, we developed preclinical trials in glioblastoma mouse and PDX models with LDHA inhibitors stiripentol and isosafrole42 and found that these treatments extend the survival of tumor-bearing mice via blockade of tumor-macrophage symbiosis. Here, LDHA is linked to glioblastoma.